A Review on Biosimilars - A Wheel of Fortune for Indian Pharma Industries

Surya Krishnan, Amitha Serah Mathew, Anila K N*
Department of Pharmacy Practice, Amrita School of Pharmacy, Kochi, Amrita Vishwa Vidyapeetham, Amrita University, India.
*Corresponding author’s E-mail: anilakn@aims.amrita.edu

Accepted on: 20-08-2016; Finalized on: 31-10-2016.

ABSTRACT
A bio similar is an organic product that is endorsed in view of a demonstrating that it is exceptionally like a FDA-approved natural product. They are practically identical to generics as in they are endorsed substitutes for particular bio-built treatments, or biologics. Thus, biosimilars are “comparable yet not the same” or at the end of the day biosimilars are “the twin yet not the clone” to the first biologic pioneer item. The troubles/barriers with bio similar are that, the two bio similar have a different beginning, have identical therapeutic effect, may additionally have different side-effects and for this reason require thorough testing. The European Medicines Agency (EMA) turned into the principal administrative office to affirm a bio similar. The Indian generics in industry got its first massive break in 1984, when the US surpassed what is referred to as Hatch-Waxman act. Biosimilars marketplace in India presently includes eight biosimilars. India has effectively ventured out to tap the rising open door in the biosimilars’ space. Main aim of bio similar offers guaranteed increase in patient access to the biological therapy and health care cost. In India bio similar has engrossed large investments in the areas of research, clinical trials and manufacturing.

Keywords: Biosimilars, reference product, India Pharma Industry.

INTRODUCTION
Bio pharmaceutical drugs have turned into cutting edge of pharmacotherapy in the healthcare. These include proteins got from recombinant DNA innovation and hybridoma method. Cases incorporate natural proteins (cytokines, hormones, and thickening variables), monoclonal antibodies, immunization, cell and tissue based treatments. Living creatures, for example, plant and creature cells, microbes, infections and yeast are utilized for the generation of bio pharmaceuticals.

Bio pharmaceuticals can possibly reach up to half partake in worldwide pharmaceutical market sector in the following few years. The expiry of patent insurance of numerous bio pharmaceuticals has started the improvement of a class of option variants of pioneer bio pharmaceuticals known as bio similars. Due to the auxiliary and assembling complexities, these organic items are considered as comparative, yet not nonspecific reciprocals of trailblazer bio pharmaceuticals. The expression of bio similar is like "take after on biologics" is more mainstream in the American connection.

A bio similar is an organic product that is endorsed in view of a demonstrating that it is exceptionally like a FDA-approved natural product, and has no clinically significant contrasts regarding security and adequacy from the reference product.

An interchangeable natural product is bio similar to a FDA-affirmed reference product and meets extra measures for compatibility. A compatible organic product might be substituted for the reference product by a drug specialist without the intercession of the social insurance supplier who endorsed the reference product. They are practically identical to generics as in they are endorsed substitutes for particular bio-built treatments, or biologics. At the same time generics are particular concoction duplicates of the small particle therapies they supplant, bio similars include just the restoratively dynamic segment of larger molecule biologics. Bio similars are expansive atom treatments that are produced through organic procedures in alleged bio reactors containing specific biological systems. In that capacity, they are harder to fabricate and require a more noteworthy arrangement of specialized skill.

Biologics, considered one of the quickest developing segments of the pharmaceutical sector, has acquainted numerous new medicines with life-threatening and uncommon ailments. Accordingly, investigate based and non-specific pharmaceutical organizations alike are seeking after the chance to create nonexclusive substitutes for unique biologics, in this alluded to as bio similars dissimilar to non-specific pharmaceuticals, it is difficult to create the same or indistinguishable duplicate of a pioneer product.

Thus, bio similars are "comparable yet not the same" or at the end of the day bio similars are “the twin yet not the clone" to the first biologic pioneer item. Hence the field of bio similars presents a few critical difficulties, including. :

i) Verification of the likeness,
ii) The compatibility of bio similars and trend-setter products,
iii) The conceivable requirement for special naming to separate the different bio pharmaceutical products.
iv) Administrative structure.

v) Commercial open doors and in addition rules to help makers in item advancement

vi) Intellectual property rights

vii) Public well-being.

An emphasis point in the pharmaceutical business has lingered with the endorsement of Hospira's bio similar adaptation of Remicade in Europe and the ensuing endorsement in the US. of its first bio similar, Novartis' Zarxio (which focuses on Amgen's Neupogen). In this way, the industry has experienced patent precipices because of bland adaptations of little atom drugs hitting the business sector, with biologics staying very much ensured because of absence of suitable endorsement rules.\textsuperscript{10}

The troubles/barriers with bio similar are that, the two bio similar have a different beginning, the two bio similars may also have identical therapeutic effect, may additionally have different side-effects and for this reason require thorough testing.\textsuperscript{11}

The main reason of bio similar drug development is the expiry of patent protection for lots biological medicines. [Table 1].\textsuperscript{12-14}

<table>
<thead>
<tr>
<th>PRODUCTS</th>
<th>Biopharmaceuticals</th>
<th>Indication</th>
<th>US patent status</th>
<th>EU patent status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutropin (Somatropin)</td>
<td>Genetech</td>
<td>Growth disorder</td>
<td>Expired</td>
<td>Expired</td>
</tr>
<tr>
<td>Abbokinase (Eudurase Urokurnase)</td>
<td>Abbott</td>
<td>Ischemic events</td>
<td>Expired</td>
<td>Expired</td>
</tr>
<tr>
<td>Humulin (Recombinant Insulin)</td>
<td>Ali lily</td>
<td>Diabetes</td>
<td>Expired</td>
<td>Expired</td>
</tr>
<tr>
<td>Ceredes e(Algucerase)</td>
<td>Genzyme</td>
<td>Gaucher disease</td>
<td>Expired</td>
<td>Expired</td>
</tr>
<tr>
<td>Streptase (Streptokinase)</td>
<td>Astra zenera</td>
<td>Ischemic events</td>
<td>Expired</td>
<td>Expired</td>
</tr>
<tr>
<td>Intron ATM (IFN-ALPHA 2b)</td>
<td>Biogen/roche</td>
<td>Hepatitis b and c</td>
<td>Expired</td>
<td>Na</td>
</tr>
<tr>
<td>Serotim (Somatropin)</td>
<td>Serono</td>
<td>Aids wasting</td>
<td>Expired</td>
<td>Na</td>
</tr>
<tr>
<td>Humatrope (SOMATROPIN)</td>
<td>Eli lily</td>
<td>Gaucher disease</td>
<td>Expired</td>
<td>Expired</td>
</tr>
<tr>
<td>Epogen, Procrit, EPRES (Erythropoietin)</td>
<td>Amgen</td>
<td>Anemia</td>
<td>Expired</td>
<td>Expired</td>
</tr>
<tr>
<td>Neorecormon (Erythropoietin)</td>
<td>Roche</td>
<td>Anemia</td>
<td>Na</td>
<td>Expired</td>
</tr>
<tr>
<td>TNKase (Tenecteplase TNK-tPA)</td>
<td>Genetech</td>
<td>Acute myocardial infarction</td>
<td>Expired</td>
<td>Expired</td>
</tr>
<tr>
<td>Actimmune(IFN-GAMMA Ib)</td>
<td>Inter mune</td>
<td>Cgd, malignant osteopetrotin</td>
<td>Expired</td>
<td>Expired</td>
</tr>
<tr>
<td>Alteplase(TPA)</td>
<td>Genetech</td>
<td>Acute myocardial infarction</td>
<td>Expired</td>
<td>Expired</td>
</tr>
<tr>
<td>Proleukin(IL-2)</td>
<td>Chiron</td>
<td>HIV</td>
<td>Expired</td>
<td>Expired</td>
</tr>
<tr>
<td>Neupogen(Filgrastim G-CSF)</td>
<td>Amgen</td>
<td>Anemia, leukemia, neutropenia</td>
<td>Expired</td>
<td>Expired</td>
</tr>
</tbody>
</table>

CDSCO forthwith said that the reference biologic can be licensed in complete ICH country (i.e. EU, Japan, US, Canada and Switzerland), if the reference biologic (the developed bio similar) is not marketed in India.\textsuperscript{15}

Indian companies face several challenges in accepting the regulatory approbation in the market due to the involute nature of bio similars.

Bio similar industry has several advantages and disadvantages.\textsuperscript{16}

Advantages:

- Low cost and similar effectiveness of the original product.
- Limited time is required to market than the original product
- High chance of return of investment(ROI) than the new product R&D.
- Discount in expensive healthcare treatment.

Disadvantages:

- Large Financial support is required due to rising regulatory requirements.
- According to consumers cost of bio similar products are comparatively higher than the small molecule generic which is heavy reduction than the original product.
● Lack of understanding and reliability of industry.

**HISTORY**

In the 9 years since the European Medicines Agency (EMA) turned into the principal administrative office to confirm a bio similar, more than 20 bio similar items have been endorsed in Europe, and some of these bio similars have additionally been affirmed as bio similars in Australia, Japan, and/or Canada. In the United States (US), the Food and Drug Administration (FDA) is relied upon to endorse its first bio similar this year. Furthermore, numerous nations outside of the exceedingly directed markets have endorsed alleged take after on biologics, which, not at all like bio similars in the US, Japan, Australia, and Europe or ensuing section biologics (SEBs) in Canada, are created to duplicate a reference item yet have not been subjected to no holds barred similar studies with that reference item to meet the same endorsement norms as in the very controlled markets. These take after on biologics give basic access to these medications for patients, however ought not be mistaken for bio similars or SEBs or items that have experienced this thorough testing.17,18

**BIO SIMILARS IN INDIA**

The Indian generics in industry got its first massive break in 1984, when the US surpass what is referred to as Hatch-Waxman act. With this legislation, the United States streamlined the non-precise endorsements alongside those lines making it much less demanding for non-specific organizations to contend the US drug market.19

India is known for manufacturer of small-molecule active pharmaceutical components (APIs) for Western pharmaceutical groups, particularly inside the generics quarter. However, India's cutting-edge worldwide pharmaceutical production money owed for about 8% of all, and India's contract production market is emerging three times the charge of the worldwide agreement marketplace.20

On 28th March 2016 Central Drugs Standard Control Organization delivered new guidance for biosimilar developers as new biosimilars attain to marketplace earlier than other regions, and as India's regulators should try to develop more precise steering on postmarketing studies.21

The audit board of trustees on hereditary manage of the Genetic Engineering Approval Committee (GEAC) with the authorization of DCGI, choose clinical trials to be directed in India diagnosed with biosimilar helpful merchandise. The biosimilar needs to show nearly same statistics of non-clinical research viz., pharmacokinetics and toxicology (security pharmacology, multiplication toxicology, mutagenecity and most cancers-causing nature) and clinical research (viability and decency for every signal) before it gets endorsement for all sign of the reference answer.

Biosimilars marketplace in India presently includes eight biosimilars, along with one for AbbVie's blockbuster Humira (adalimumab) and two biosimilars for Roche's breast cancer remedy, Herceptin (trastuzumab), which aren't authorized in every other countries (although Korea's food and Drug administration has authorized a distinctive Herceptin biosimilar), in line with the enterprise weblog Biosimilariz (the Generics and Biosimilars Initiative lists more than 60 authorized biosimilars in India). Monoclonal antibodies (MAB) play a chief position in chemotherapy, so most of the biosimilar entrepreneurs are focused on the production MAB22.

Indian companies marketing biosimilars in India23 (Table 2)

<table>
<thead>
<tr>
<th>Company (location)</th>
<th>Product description</th>
<th>Biosimilar</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Reddy's Lab (Hyderabad)</td>
<td>Filgrastim (recombinant granulocyte-macrophage colony-stimulating factor, G-CSF)</td>
<td>Grafeel</td>
</tr>
<tr>
<td>Intas (Ahmedabad)</td>
<td>Filgrastim (recombinant G-CSF)</td>
<td>Neukine</td>
</tr>
<tr>
<td>Shantha Biotech/ Merieux Alliance (Hyderabad)</td>
<td>Recombinant human interferon alpha-2b</td>
<td>Shanferon</td>
</tr>
<tr>
<td>Reliance Life Sciences (Mumbai)</td>
<td>Recombinant erythropoietin</td>
<td>ReliPoiitin</td>
</tr>
<tr>
<td>Wockhardt (Mumbai)</td>
<td>Recombinant erythropoietin</td>
<td>Wepox</td>
</tr>
<tr>
<td>Biocon (Bangalore)</td>
<td>Recombinant human erythropoietin</td>
<td>Eripro</td>
</tr>
<tr>
<td></td>
<td>Recombinant streptokinase</td>
<td>Shankinase</td>
</tr>
<tr>
<td></td>
<td>Recombinant erythropoietin</td>
<td>Shanpoietin</td>
</tr>
<tr>
<td></td>
<td>Recombinant human interferon alpha-2b</td>
<td>ReliGrast</td>
</tr>
<tr>
<td></td>
<td>Recombinant interferon alpha-2b</td>
<td>ReliFeron</td>
</tr>
<tr>
<td></td>
<td>Recombinant reteplase (tissue plasminogen activator)</td>
<td>MIRel</td>
</tr>
<tr>
<td></td>
<td>Recombinant streptokinase biosimilar</td>
<td>Myokinase</td>
</tr>
<tr>
<td></td>
<td>Recombinant human insulin</td>
<td>Insugen</td>
</tr>
</tbody>
</table>

There are 25 Indian bio similars industry marketing close to 50 products in the Indian market and few of these in some unregulated markets. Now the market is shifted
towards diseases such as cardiac, diabetic and oncology due to its complex biotech drug. Increase number of tertiary care hospital resulted in practice increase of biotech products\(^\text{16}\).

India has effectively ventured out to tap the rising open door in the bio similars’ space. While all significant Indian medication creators have laid out arrangements, distinguished products and put aside speculation spending plans to build up a powerful product pipeline, some have even begun moving them into the market sector. Case in point, Dr Reddy’s Laboratories has as of now dispatched a couple of its huge bio similars in developing markets. Then again, industries like Cipla are making enormous interests in India and outside to obtain fabricating offices and potential products pipelines in the bio similar fragment. The organization has not just gained offices in India and China to create bio similars, all the more as of late, it has additionally rejigged some of its interests in China to redirect more finances towards bio similar\(^\text{16}\).

**Challenges**

Comparative biologics are created through consecutive procedure to show the comparability by broad characterisation examines uncovering the atomic and quality ascribes concerning the reference biologic. Bio similars must be efficiently built to coordinate the reference item. A similarity exercise must be taken after with the pioneer item at all levels of item advancement, including: physicochemical traits, organic action, pre clinical in vivo likeness, Phase I PK and well being, and Phase III viability and security.

This can be troublesome on the grounds that information for the trend-setter item will need the best way to get data about the segments of the trailblazer item is, from material that is as of now out in the commercial center. Having numerous groups of the trend-setter's product, spreading over various years, can be to a great degree accommodating amid the characterisation procedure. Wellsprings of variety between assembling of trend-setter bio pharmaceutical and bio similar are as given beneath:

- Use of various vector
- Different cell expression framework
- Different cell line development media and strategy for extension
- Different working conditions
- Different authoritative and elution conditions
- Different strategies, reagents, reference normstionally, Wockhardt and Lupin have made their raid into the corner fragment\(^\text{24}\).

ROI because of a popularity for cutting edge medications.

In spite of the fact that India has the second biggest USFDA affirmed drug fabricating plants by the United States, none of the items made in these offices can be considered as "genuine bio similars". Talking about the expense of assembling, its route higher than customary details. More often than not, a basic wellbeing worry on bio similar medications is being raised by the producers of unique biologics. This worry includes immunogenicity, which implies the way a bio similar drug incites a resistant reaction in the body. Unique biologic medication producers battle, subsequent to bio similar particles are not precisely the same as firsts and their long haul security, identified with immunogenicity, has not been tried, these medications can't be understood as having the same well-being profile as the trailblazers' biologics. Furthermore, "Free Trade Agreements (FTAs)" are additionally liable to be shrewdly utilized by the first biologic medication producers through their particular Governments, to the degree conceivable, for protecting the foothold from the show casing\(^\text{16}\).

**Stepping stones for Indian Bio similars (India)**

1. **Market sector to physicians serving the rising white collar class.**
2. **Build up clear pathway for administrative endorsement of products.**
3. **Enormous opportunity for interest in Indian market sector.**
4. **Set up partnerships with global industry pioneers.**
5. **Fare to unregulated and semi regulated nations**

**1. Market sector to physicians serving the rising white collar class.**

As new white collar class keeps on rising in India and other creating economies, interest for high quality, reasonably estimated biosimilars product is prone to increment.

**2. Build up clear pathway for administrative endorsement of products**

Straightforward endorsement procedure will expand product quality and decline and ideal opportunity to advertise for reasonable and possibly life saving biosimilar products, changing the administrative environment will expand Indian biosimilars organization credibility and give a stage to enter other controlled worldwide markets in the future.

**3. Enormous opportunity for interest in Indian market sector**

The necessity of serious examination and clinical trial requests extensive scale venture for biosimilar industry expanded subsidizing will permit Indian organizations to manufactured powerful product pipelines and expansion the quantity of products that come to advertise.
4. Set up partnerships with global industry pioneers.

Access to best in class labs, experience with rigorous clinical trial and financing to bolster these exercises imply that international pharmaceutical giants have much to offer India based market sector contestants. A lower R&D and manufacturing cost structure and exceptionally talented work power make India a perfect area for global organizations hoping to lessen cost and expand edges.

5. Fare to unregulated and semi regulated nations

Because of less administrative obstacles, creating nations are the most appealing fair opportunities in the transient. In the long haul, create nations are the most critical income era and ROI because of a popularity for cutting edge medications.

CONCLUSION

Main aim of bio similar offers guaranteed increase in patient access to the biological therapy and health care cost. In India bio similar has engrossed large investments in the areas of research, clinical trials and manufacturing. They provide numerous expansion and investment opportunities for India and foreign player. The Indian government should ensure that instructions to improve quality control and administrative oversight are upheld, and that training programs for both biologics administrative endorsement and assembling practices are moved ahead. Extra noteworthy coordinated attempt among Western and Indian groups implies cultivating an unusual degree of association between the two. In any case, the outcome—new quality products that are available to more people for much less—might be justified irrespective of the exertion.

REFERENCES

1. Professor Paul J Declerck PhD;Biologicals And Biosimilars;a review of the Science and its Implications;Generics and Biosimilars initiative (GaBI Journal).2012;1(1):13-6


3. Blanchard, A., Helene D'Iorio and Robert Ford. "What you need to know to succeed: Key trends in Canada's biotech industry " Insights, spring 2010


5. Follow-On Protein Products;Regulatory And Scientific Issues Related To Developing ; [Last accessed on 2013 Jul 15; Published on 2015 April 09] Available from: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/ucm085854.htm

6. Approval Pathway for Biosimilar and Interchangeable Biological Products Public Meeting;FDA;November 2-3 2010.FDA page on "Approval Pathway for Biosimilar and Interchangeable Biological Products Public Meeting"


9. FDA Approves First Biosimilar Product Zarxio;FDA;March 6 2015. FDA page on ”FDA approves first biosimilar product Zarxio.[Last accessed on 2016 Jul 15; Published on 2015 March 06]


21. Biosimilars In India News:Recent Guidelines from Indias CDSCO and a pending case on “Biosimilar”Trastuzumab;May 6 2016;Big Molecule Watch. Available from

International Journal of Pharmaceutical Sciences Review and Research
Available online at www.globalresearchonline.net

© Copyright protected. Unauthorised republication, reproduction, distribution, dissemination and copying of this document in whole or in part is strictly prohibited.


24. India can emerge as a Key Player in the Biosimilar Segment; Chemtech Foundation; Pharma Biotech. Available from http://www.chemtech-online.com/P&B/Ramniwas_april13.html

Source of Support: Nil, Conflict of Interest: None.